Skip to main content
. Author manuscript; available in PMC: 2018 Jun 18.
Published in final edited form as: Leukemia. 2017 Aug 14;32(1):203–213. doi: 10.1038/leu.2017.250

Figure 7. SHP2 affects distinct transcriptional programs in WT and BCR-ABL1+ pre-B cells.

Figure 7

(a) Validation of differential expression of cell cycle regulatory genes by q-RT-PCR (n = 4). Ccnd1, Cdkn2c, and Cdkn2d are regulated by SHP2 in in BCR-ABL1+, but not WT, pre-B cells. (b) qRT-PCR validation of genes involved in regulation of MYC transcription (n = 4). The log ratios of Mxd3 or Mxd4 transcription levels in SHP2-deficient vs SHP2-replete cells are shown. Mxd3 and Mxd4 mRNA levels are not regulated by SHP2 deficiency in WT pre-B cells, but are significantly up-regulated in BCR-ABL1+ pre-B cells. (c) BCR-ABL1+ SHP2-deficient (−/−) or replete (+/+) pre-B cells were treated with U0126 and/or SU6656 at indicated concentrations for 2 days. Relative mRNA levels for Mxd3 were quantified (n = 4). Transcription levels were compared with SHP2-replete BCR-ABL1+ vehicle control (denoted by “*”) or SHP2-deficient control (denoted by “#”) groups. (*P < 0.05, **P < 0.01, ***P < 0.001, ##P < 0.01, ###P < 0.001; ANOVA with Bonferroni post-test).